# NUTRITIONAL IMMUNITY, ZINC SUFFICIENCY AND COVID-19 MORTALITY IN SOCIALLY SIMILAR EUROPEAN POPULATIONS

**Samer Singh, PhD [1#]; Amita Diwaker, MBBS, MS[2]; Brijesh P. Singh, PhD[3]; Rakesh K. Singh, PhD[4]**

[1]Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

[2]Department of Obstetrics and Gynecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

[3]Department of Statistics, Institute of Science, Banaras Hindu University, Varanasi – 221005, India

[4]Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi – 221005, India

[#] **Address for correspondence:** samer.singh10@bhu.ac.in; **ORCID ID:** https://orcid.org/0000-0002-0921-1686

*ABSTRACT:*

The impact of Zinc (Zn) sufficiency/supplementation on COVID-19 associated mortality and incidence (SARS-CoV-2 infections) remains unknown. During an infection, the levels of free Zn are reduced as part of 'nutritional immunity' to limit the growth and replication of pathogen and the ensuing inflammatory damage. Considering its key role in immune competency and frequently recorded deficiency in large sections of different populations, Zn has been prescribed for both prophylactic and therapeutic purposes in COVID-19 without any corroborating evidence for its protective role. Multiple trials are underway evaluating the effect of Zn supplementation on COVID-19 outcome in patients getting standard of care treatment. However, the trial designs presumably lack the power to identify negative effects of Zn supplementation, especially in the vulnerable groups of elderly and patients with comorbidities (contributing 9 out of 10 deaths; up to >8000-fold higher mortality). In this study, we have analyzed COVID-19 mortality and incidence (case) data from 23 socially similar European populations with comparable confounders (population: 522.47 million; experiencing up to >150 fold difference in death rates) and at the matching stage of the pandemic (12 March - 26 June 2020; 1st wave of COVID-19 incidence and mortality). Our results suggest a positive correlation between populations' Zn-sufficiency status and COVID-19 mortality ($r$(23): 0.7893–0.6849, *p*-value<0.0003) as well as incidence [$r$(23):0.8084 to 0.5658; *p*-value<0.005]. The observed association is contrary to what would be expected if Zn sufficiency was protective in COVID-19. Thus, controlled trials or retrospective analyses of the adverse event patients' data should be undertaken to correctly guide the practice of Zn supplementation in COVID-19.

**Key Words:** COVID-19, Nutritional Immunity, Zinc, Infection, Micronutrient, Oxidative Stress, Redox, Mortality, Elderly

***INTRODUCTION*:**

Zinc (Zn) is a redox-neutral key micronutrient that plays an important role in immune competence and wellbeing (1-3). Worldwide, the explicit and implicit general recommendations for immune augmentation of the supposed 'Zn-deficient' population components and COVID-19 patients by healthy diet or Zn supplementation are in place. The 'COVID-19 treatment panel guidelines' of the Centre for Disease Control (CDC), USA, and others seemingly suggest Zn supplementation as an adjunctive therapy option 'to complement the presumed protective role of Zn in infections and other immune and oxidative stress-related conditions/pathologies relevant to COVID-19 (4-7). A surge in the number of articles advocating a role of Zn supplementation in COVID-19 treatment/management has been observed.  A search with keywords '((Zinc) AND (COVID-19)) AND (treatment)' had yielded 117 articles in PubMed on 14 Jan 2021(8). Speculative benefit from Zn supplementation in COVID-19 has fueled its widespread prescription and over-the-counter purchases. This practice has gained momentum due to incorrect interpretation and implementation of CDC's guidelines, inability to accurately assay Zn deficiency, and mild to no side effects of Zn overdose in healthy individuals. The actual figures of the total increase in Zn supplementation worldwide as a result of the COVID-19 pandemic are not in the public domain but from news articles, it may be surmised that it had already registered a surge by mid-April of 2020 and have steadily increased in different markets/countries since then (9-11). However, the clinical evidence supporting any beneficial effect of Zn supplementation or the ecological association studies supporting the potential positive impact of Zn sufficiency of the population/individuals on COVID-19 disease is nonexistent. Apparently, the push for Zn supplementation in COVID-19 is fueled by observed *in vitro* suppression of viral replication including that of coronavirus by high-doses of Zn [12, 13] which are physiologically irrelevant and would be unattainable *in vivo*. Globally, Zn deficiency among populations ranges from 3-54% (14). The developed European and North American nations generally have the highest sufficiency while African and Asian nations have the least. Its deficiency in populations is widely associated with vulnerability to infectious diseases, chronic immune system disorders, and other medical conditions (3-5,7,14,15).

The Zn levels are tightly regulated in the human body and its differential levels are maintained in various organs, tissues, and extracellular milieu including serum through a complex homeostasis mechanism involving multiple regulators and transporters (1, 16-18). Optimal levels are maintained in different tissues, organs as well as immune cells to regulate inflammation and pathogen clearance, reduce reactive oxygen radicals, and affect various bodily processes including lipid metabolism and glucose levels. During infections, the levels of Zn are reduced in serum and it is redistributed to tissues and immune cells as a part of 'nutritional immunity' to enhance immune cells' function and check pathogens' growth and replication (1, 16, 18, 19). The intracellular Zn reserves are also mobilized and reallocated in the presence of intracellular pathogens in an attempt to reduce the availability of free Zn to limit their survival and replication potential.  Simultaneously, it signals the neighboring cells about the presence of pathogens and induces a balanced inflammatory response (REFs in 1, 2, 16, 18, 19). Zn insufficiency is associated with frequent infections and chronic inflammation. Due to the unavailability of accurate measures (assays) to diagnose Zn deficiency, serum levels along with relevant deficiency symptoms are used to prescribe Zn supplements in pathologically deficient individuals. Nonetheless, Zn supplementations are known to promote adverse effects in several disease conditions which are currently also identified as comorbid conditions for COVID-19 patients and frequently observed in the elderly, *e.g.*, sickle cell disease, chronic kidney diseases (CKD), cardiovascular diseases (CVD), and coronary heart disease (CHD) (15,20-23).

We hypothesized if higher Zn levels would be playing the supposed protective role against COVID-19,
the COVID-19 associated mortality (and incidence) would negatively covary with the Zn sufficiency of
populations. The European populations that experienced the 1st wave of SARS-CoV-2 infections
simultaneously and had more similar confounders, such as, high Healthcare Access and Quality (HAQ)
Index, life expectancy, median age (24,25), etc. as compared to other parts of the world, offer an
excellent opportunity to test such assertions. These relatively similar populations had been also
previously analyzed for proposing other potential protective variables (26-31) and variously referred to
as socially similar. In the current study, first waves' phase-matched pandemic data of socially similar
European populations with supposedly comparable confounders were analyzed to test the null
hypothesis that Zn sufficiency is not correlated with COVID-19 associated mortality (and incidence).

***MATERIAL AND METHODS:***

**Study populations and Zn sufficiency status:** The COVID-19 incidences and mortality data of
twenty-three socially similar European populations (Total 522.47 million) with similar confounders (26-
30) were collected from Worldometer's coronavirus webpage (24). The data for the 1st wave of SARS-
CoV-2 infections in these countries (12 March to 26 June 2020) are presented as COVID-19 cases per
million (CpM) and Deaths per million (DpM) in Table 1 (see Supplementary Table 1 for extended
dataset up to 26 August 2020). The populations' Zn sufficiency/deficiency level estimates were from
Wessells and Brown, 2012 (14). For an overview of the worldwide country-wise Zn sufficiency of the
populations and COVID-19 impact refer to Supplementary Figure 1. The notification rates of COVID-19
deaths and incidences in different socially similar European populations during the passage of SARS-
CoV-2's 1st wave-of-infections are provided in Supplementary Figure 2. The European countries with
comparable confounders and at a similar phase/stage of the pandemic were selected for the current
analysis to arrive at more dependable conclusions (26,28,29,31).

**Statistical analysis:** In order to examine the relationship between the prevalence of Zn sufficiency and
deaths in the populations due to COVID-19, we obtained a Pearson correlation coefficient that provides
the degree of relationship in real number, independent of the units in which the variables have been
expressed and also indicates the directionality of the relationship, *i.e.*, positive or negative. The formula
for the Pearson's correlation coefficient is as follows

$$r = \frac{n\left(\sum xy\right) - \left(\sum x\right)\left(\sum y\right)}{\sqrt{\left[n\sum x^2 - \left(\sum x\right)^2\right]\left[n\sum y^2 - \left(\sum y\right)^2\right]}}$$ ; where *x* and *y* are the variables of interest and *n* is the

number of paired observations.

We aimed to fit several statistical models including both linear and non-linear models for the empirical
data. Various types of models were tested and among these, the best-fitted models have been
considered here. For non-linear models, polynomials have been considered which can be
mathematically expressed as:

$$Y = \alpha + \sum_{i=1}^{n} \beta_i x^i, (\beta_i \neq 0; i = 1, 2, ...., n)$$

Where $\alpha$ is the constant, $\beta_i$'s (i=1,2,….n) are the regression coefficient of $X_i$'s (i=1,2,….n) and $X$ is the
independent variable, i.e., Zn sufficiency and $n$ is a positive integer referred to as polynomial of degree
$n$. For $n$=0, it becomes a constant function, whereas for $n$=1, it is a polynomial of degree 1 (i.e., a
simple linear function), and for $n$=2 it is a polynomial of degree 2 (i.e., quadratic polynomial). For
different degrees of polynomials the models employed can be simply expressed as under:

*Linear model:* $Y = \alpha + \beta X$; *Quadratic model:* $Y = \alpha + \beta_1 X + \beta_2 X^2$;    $\beta_1, \ \beta_2 \neq 0$;

For the exponential curve, the relationship is mathematically expressed as $y = \alpha e^{\beta x}$. The explanation
of various parameters (coefficients) of the models is that for a unit change in *'X'* we observe a change
in '*Y'* equal to the value of respective coefficients. All the computations were performed in Microsoft
Excel. COVID-19 mortality and incidence, without applying extra exclusion/inclusion criterion of the risk
factors or supposed confounders (e.g., age, sex, age distribution, comorbidities, populations' density,
etc.), were assessed for correlation with populations' Zn sufficiency, as done previously (26, 29).
Interim case fatality ratio (i-CFR) for the populations/groups were calculated as '(reported
deaths/reported cases)*100. P-value <0.05 was considered statistically significant.

**Epidemiological map display and required color manipulation:** Global maps showing country-wise
Zn levels, as well as COVID-19 incidence and deaths, are adapted from (25). The Choropleth maps
displaying the variation of variables for the selected countries were created using 'Inkscape' software.

*RESULTS***:**

The socially similar countries selected for the analysis had been more severely affected by the COVID-
19 as compared to other parts of the world despite being some of the least Zn deficiency countries
(Supplementary Figure 1). Similarly, the nations of North America with higher Zn sufficiency levels were
also found to be more severely affected by COVID-19 as compared to other parts of the world with
lower Zn sufficiency. The European nations included in the current analysis were almost at a similar
stage of pandemic (Supplementary Figure 2). The nations included in the current study had registered
only 15.71% cases (1552 thousand cases) of the total global cases (incidences) by 26 June 2020 but
about 34.2% of total global deaths (173 thousand deaths). As the wave of SARS-CoV-2 infections
spread to other parts of the world by 26 August 2020, the relative contribution of the selected countries
changed to 8.85% of cases and 21.78% of total global COVID-19 deaths. Nevertheless, the mortality
rate remained disproportionately high in countries with better Zn sufficiency. The correlation (Pearson's)
and regression analysis were performed on these twenty-three socially similar European populations'
Zn sufficiency levels and COVID-19 incidences and mortality data (12 March to 26 June 2020) without
considering any additional exclusion/inclusion criterion. The observations made are briefly summarized
below:

1.  ***Globally COVID-19 mortality rates positively correlate with Zinc sufficiency levels***: Zn
sufficiency/deficiency levels vary across the globe (Supp. Fig. 1). Generally, differential COVID-19
mortality rates had been observed among countries. The European and North American countries
with higher HAQ index, life expectancy, median age (24, 25) came out as the worst affected.
Previously, trained-immunity (26, 27), BCG vaccination (28), vitamin D (29), Zn deficiency (30)
had been associated with reduced COVID-19 mortality using early-stage pandemic data (26-30).
They had also attracted criticism for the inappropriateness of the data set, inclusion/exclusion

criteria, non-matched pandemic stages among countries, and more importantly the loss of association by mid- or post-peak-of-infections (REFs in 25, 27, 29, 31). Globally the populations were exposed to COVID-19 at different time points, had different lifestyles, social structures, preventive measures in place, and access to medical facilities. So, the supposed associations drawn from them could be tenuous due to disparate data sets. To arrive at more dependable conclusions, when the pandemic phase-matched (Supp. Fig. 2) populations with comparable confounders (26,28,29,31) were analyzed for the COVID-19 mortality rate in socially similar populations [Boxed North America (NA) and European Union (EU)], it strongly associated with their Zn sufficiency (Supp. Fig 1; time-series graphics available at reference 25). Incidentally, the countries of Europe, North America, and South America that have reported high mortality have been also the high Zn sufficiency countries.

2. ***Zinc sufficiency strongly and significantly correlated with COVID-19 mortality in socially similar countries:*** The Zn sufficiency in twenty-three socially similar European populations (Fig 1A, Table 1) was positively associated with reported COVID-19 deaths and cases per million (Fig. 1B-C). The COVID-19 associated mortality rate (deaths/million) and incidence rate (cases/million) covaried exponentially with Zn sufficiency of the populations (Fig. 1D-E). The populations with Zn sufficiency >92.5% had experienced up to 9X higher deaths per million population (Fig. 1D). Pearson's correlation for the synchronized period of reported COVID-19 cases and deaths among the countries (26 April to 26 June, Supp. Fig. 2), was strong [Table 2, Deaths per million: $r(23)= 0.7455–0.6849$, $p<0.0003$; Cases per million: $r(23)= 0.8084–0.7629$, $p<0.00002$]. The division of countries using >93.7% sufficiency cutoff, indicated high mortality (5.79 to 2.66X) and incidences (4.5 to 2.3-fold) in high Zn sufficiency populations (n=12) as compared to low sufficiency populations (n=11). Some of the outlier populations that fared extremely well and displayed quite low mortality among the higher Zn sufficiency countries, *e.g.*, Iceland, Finland, Norway, Denmark, also happen to have higher levels of 'trained immunity' and serum 'vitamin D' levels - two other protective variables proposed earlier (26, 27, 29).

3. ***Higher Zn sufficient socially similar countries/populations consistently reported higher COVID-19 case fatality rates (CFRs) and incidence rates:*** The CFRs for the group of countries with higher Zn sufficiency (>93.7%, 12 countries) remained higher than that for the group of countries with lower Zn sufficiency (<93.7% 11 countries) throughout the study period (till 26 August 2020; Fig. 1 F). It started to decline post-peak-of-infections, *i.e,* 12 May 2020. This could be reflective of more uniform reporting in later stages of the pandemic or decreased load on medical infrastructure resulting in better patient care and lower adverse outcomes. The relative difference in the COVID-19 cases per million between two groups of countries decreased over time but the rate of CFR decrease had been slower in high Zn sufficiency populations than that in lower Zn sufficiency populations, resulting in a progressively increasing CFR gap between the two sets of countries during the study period (a CFR gap of 16% on 26 June become 30 % by 26 August 2020) (Fig. 1G).

### *DISCUSSION AND CONCLUSION:*

Overall a general positive correlation of COVID-19 mortality and cases of populations with their Zn sufficiency levels was observed during the 1st wave of SARS-CoV-2 infections, which sustained even

on flattening of the curves. The socially similar European populations with comparable potential confounders which were also at a similar stage of the pandemic and had reported more than 399 cases per million population were included in the correlation analysis. This group of high COVID-19 impacted countries globally accounted for 34.2% mortality (173 thousand deaths) by 26 June 2020, giving confidence to the observations made. The correlation of Zn sufficiency of the study populations with COVID-19 mortality and cases for the whole study duration was similar to that was observed previously with an earlier phase COVID-19 pandemic data of a smaller set of countries [30]. The correlation remained stable and statistically significant for the whole study period encompassing the relevant phase of the wave-of-infections, unlike other risk factors or protective variables proposed previously using early phase pandemic data (27,29,31). The association observed in the current study is even stronger than those being actively discussed, debated and evaluated in clinical trials (28, 29, 31). It may be suggested that the association observed warrants a thorough investigation to arrive at a more meaningful conclusion about the role of Zn supplementation in COVID-19 outcomes.

It would be pertinent here to discuss the limitations of the data set used for the current analysis. The COVID-19 data had been collated by different agencies and had been subject to adjustments from time to time. Depending upon the aggregators, there also exist some minor differences between different COVID-19 databases, e.g., during 1$^{st}$ wave of infections the maximum cases reported per day by Ireland as per 'https://coronavirus.jhu.edu/map.html' were 1515 cases on 10/04/20, while it was 1508 as per 'Worldometer'. Similar size adjustments of the data could affect the early-stage data analysis more drastically than the adjustment made to later-stage data - making the early-stage associations inherently less reliable. The Zn deficiency/sufficiency estimates for the populations used in the current analysis are for the year 2005 that was published in 2012 (14). The estimate was based upon the food balance sheets, the bioavailability of Zn in the food supply, estimated physiological requirement of Zn in individuals, population demographics, and stunting observed in children. The revision of the Zn deficiency/sufficiency estimates for populations is long overdue. Since the estimates published by Wessells and Brown, 2012 remain the latest, they had been used as an approximation for the current levels of populations. However, for the sake of current analysis and discussion, it may be assumed that drastic negative changes in Zn sufficiency levels have not happened among these countries and the overall relative Zn sufficiency levels would have been maintained. The general improvement in the development index and the availability of diverse foods and supplements along with reduced stunting in children in the last two decades as per data available with the Food and Agriculture Organization (FAO) of the United Nations (UN) and World Health Organization (WHO) further strengthens the notion. The analysis presented in the current study may need to be revisited whenever more accurate Zn sufficiency/deficiency estimates of the populations for the current period become available. The availability of COVID-19 patients' data concerning Zn supplementation and dietary food intake during COVID-19 is expected to provide the most accurate picture of the association.

The Zn bioavailability reduction during infections is a common component of 'nutritional immunity' (1, 16, 19, 32). The drop in serum Zn levels is primarily attributed to a proinflammatory cytokine-mediated alteration in the expression of hepatic Zn transporter proteins during the acute phase of inflammation through squelching of serum Zn coming from the diet (33). The cell-mediated Zn restrictions, reallocation, and mobilization (primarily mediated by ZIP family of transporters, *e.g.*, ZIP8 in *Mycobacterium tuberculosis* (34), as well as extracellular Zn sequestration (primarily mediated by S100 family of proteins, e.g., calprotectin, psoriasin, calgranulin, etc.), is supposed to be part of an elaborate intricate immune mechanism to both starve and/or intoxicate pathogen with this key element as per

differential need (REFs in 1, 2, 18, 19). Calprotectin, an S100A8/S100A9 heterodimer, seems to be a key player in immune regulation through its ability to chelate Zn and other metal ions (1, 35) and also serve as a damage-associated molecular pattern (DAMPs) and a ligand for Toll-like receptor 4 (TLR4) (36). It can account for >40% of cytoplasmic proteins in neutrophils during infection (37). *In vitro* studies have shown an important role of calprotectin in inhibiting the growth of the pathogens while the supplementation of Zn has been shown to revert the calprotectin-mediated growth inhibition (38-40). Here the Zn starvation strategy could primarily interfere with the Zn-dependent infection process and replication while the intoxication could help the generation of ROS in a localized manner for effective pathogen incapacitation and elimination (REFs in 1, 2, 32). The existing pieces of evidence point to the mobilization of Zn during infection as a measure to not only limit its availability to invading pathogens but also prime immune cells to kill pathogens.

Systematic reviews of Zn supplementation studies had shown a significant reduction of diarrhea incidents and the associated deaths in Zn deficient children (REFs in 41-43). It now forms a part of global diarrhea control measures. Several studies using a small set of individuals/patients do indicate a benefit of Zn supplementation in other diseases as well including pneumonia and lower respiratory tract infections which are relevant to COVID-19 (REFs in 41). However, the systematic review and meta-analysis of the previous studies do not support the supposed positive influence of Zn supplementation on the prevention and treatment of different diseases when Zn sufficient individuals were also included in studies (REFs in 41,43). Though Zn sufficiency promotes the well-being and integrity of respiratory cells during lung inflammation and protects them from injury arising from respiratory tract infections (RTI) and decrease the incidence of infections by regulating immune functions and response (44), the ability of Zn supplementation to help reduce the infection, severity or treatment of lower RTI (a comorbid condition in > 50% COVID-19 deaths) has not been unequivocally supported in different Zn sufficiency patient populations. A Cochrane Systematic review that summarized 73 studies of Zn supplementation performed in Zn-sufficient and deficient children (low and middle-income countries) up to the age of 12 years did not find evidence for the reduction in RTI (prevention) but indicated a negative effect on Cu status (42). However, when the same set of studies additionally considered the iron supplementation status a reduction in death risk ratio from RTI was observed as per the studies summarized in the WHO document available in e-Library of Evidence for Nutrition Actions (eLENA) [43]. Similarly, as per studies summarized in WHO guidelines for tuberculosis patients, Zn supplementation does not have desired beneficial effects on tuberculosis patients who chronically have lower circulating Zn levels (45). A more recently updated meta-analysis of Zn micronutrient supplementation also could not find augmentation of the tuberculosis therapy outcomes as assessed at different time points (*e.g.*, sputum-culture or sputum-smear positivity, chest x-ray clearance; death in HIV positive patients) (46). The findings of a ZINC trial, recently reported in JAMA, that evaluated the effect of Zn supplementation on survival of HIV patients – who have also suffered during the COVID-19 pandemic, were discerning (47). A detrimental effect of Zn supplementation on the overall survival of study participants was observed. The study evaluated the effect of Zn supplementation on markers of mortality, the risk of cardiovascular disease, the levels of inflammation and associated microbial translocation, and HIV disease progression among HIV-positive alcoholic veterans. It concluded that Zn supplementation did not improve any of the assessed markers among 69% of the participants (i.e., survivors) who completed the 18-month study period. A closer look at the cause of dropouts as provided in the supplementary table (eTable. 'Causes of Death in the ZINC Trial by Randomized Group') surprisingly provides a different narrative. It highlights a potentially serious detrimental impact

of Zn supplementation on a section of the HIV-infected cohort. The Zn supplemented group in comparison to the control group had observed almost two-fold higher all-cause mortality, *i.e.*, 21/126 *vs* 12/128. If we remove cases with the unknown cause of deaths from both groups, the deaths were about 3 times more frequent in the Zn supplemented group (19/126 vs 7/128). Distribution of deaths in the Zn supplemented *vs* control group concerning the COVID-19 relevant conditions (23) was more surprising, *e.g.*, HIV-related deaths: 7/21 *vs* 2/12; overdose-related deaths 4/21 *vs* 1/12; deaths from pneumonia: 3/21 *vs* 0/12; deaths from suicide: 2/21 *vs* 0/12; deaths from Thromboembolism: 1/21 *vs* 0/12.

Two notions that are supposedly contributing to the increase in Zn supplementation for COVID-19 management are, a) Zn can block viral replication, b) patients reporting COVID-19 symptoms have lower serum Zn levels. It must be remembered here that the free Zn levels required to achieve viral replication inhibition *in vivo* are not possible without killing the host (12). During infections and fever as a result of the natural 'nutritional immunity' response, the availability of cellular as well as the systemic Zn (from circulation) is reduced to impede the growth of pathogens (1, 2, 19, 48). The redistribution of Zn from circulation is part of a mechanism to limit the oxidative damage to peripheral tissues, away from circulatory or other vital systems during infections, which may experience a transient or sustained localized increase of oxidative radicals as a part of an immune response.

The serum Zn just represents <0.2 % of total Zn present in the body. There is a relative dearth of studies characterizing the effect of Zn supplementation on the kinetics of Zn serum levels during acute viral infection when the acute phase response actively keeps the Zn serum levels low. However, based upon studies in healthy subjects, neither the severe restriction of Zn in diet (e.g., <0.1-0.5 mg/day) is known to cause appreciable depletion in average serum Zn levels (upwards of 2 to 9 weeks are needed) nor the supplementation of Zn can restore the levels supposedly necessary to confer any benefit within the desired short window of 3-5 days of the crucial infection period (49). Usually upwards of 9-35 days are needed to bring the serum Zn levels back to basal levels even in individuals severely depleted of Zn levels (49). Furthermore, due to inter-individual variation in serum Zn levels and their response to Zn supplementation, serum Zn levels are never a reliable indicator of an individuals' Zn status. The remarks made by Hess et al. 2007 based upon their analysis of nine intervention trials, summarizes the Zn serum levels status as "… an individual's serum zinc concentration does not reliably predict that person's response to zinc supplementation." (whereas the) "Serum zinc concentration can be considered a useful biomarker of a population's risk of zinc deficiency and response to zinc interventions, although it may not be a reliable indicator of individual zinc status." (49, p-S403)

The variable(s) responsible for the observed association between Zn sufficiency and COVID-19 mortality remain undefined. We speculate that the increased mortality observed in high Zn sufficiency populations could be contributed by the existing underlying conditions of altered genetic composition, physiology, response to Zn supplementations/modulation in certain sections of the population [15-22,50]. It would be making them prone to display characteristic COVID-19 adverse illness as a result of increased oxygen radical generation or diminished oxidative stress handling system due to their physiologies' propensity to promote the pro-oxidant role of Zn on supplementation (2).  Furthermore, Zn overdoses would have the potential to negatively affect the activity of different Zn dependent antioxidative system components leading to oxidative stress and tissue damage, *e.g.*, the R213G polymorphism of superoxide dismutase 3 (SOD3), a key member of the extracellular reactive oxygen species (ROS) neutralization system, found in 2-6 % of the population is known to make the R213G

carrier population prone to oxidative stress promoted hypertension and increased risk of cardiovascular infractions and thrombosis (REFs in OMIM #185490 'SUPEROXIDE DISMUTASE 3; SOD3' https://www.omim.org/entry/185490; additional info at http://www.wikigenes.org/e/gene/e/6649.html) - some conditions frequently associated with COVID-19 adverse events (51). Moreover, the Zn overdose is not uncommon in the highly impacted aged population of the developed countries that are more receptive to supplementation with or without a prescription (52).

Recently published meta-analyses of drugs being prescribed worldwide as a standard-of-care and the investigational drugs being evaluated in clinical trials for COVID-19 treatment, starkly indicate that the most promising drug for alleviating COVID-19 symptoms and decreasing the mortality had been such corticosteroids alone (53,54) that also suppress the Zn levels (55-57) along with increasing levels of oxidative damage protecting metallothioneins (58-59). A similar increase in metallothionein levels had been reported for 1,25-dihydroxy vitamin D3 (60) as well, another potential protective variable for COVID-19 (29). This serum Zn level suppression property of the select corticosteroids is also shared by steroid hormone estradiols which are naturally higher in females and youngs – two broad groups that had also consistently displayed lower vulnerability to COVID-19 adverse events (23). Whether these occurrences are coincidences or have mechanistic underpinnings only future investigations would reveal.

In conclusion, the observations presented, though circumstantial, underscore the need to revisit existing Zn supplementation guidelines for COVID-19 patients. Exploratory studies should be undertaken to correctly identify different underlying comorbid conditions that could make certain Zn supplemented individuals prone to COVID-19 mortality. The outcomes could help devise more comprehensive Zn supplementation practices for minimizing COVID-19 mortality among the vulnerable.

### *ACKNOWLEDGEMENTS/ DISCLOSURES*

*Funding:* No specific source of funding was utilized for the current study. SS acknowledges the funding support to his laboratory from the Institute of Eminence (IoE) seed grant, Banaras Hindu University.

*Conflict of interest:* There is no conflict of interest to disclose.

*Ethical statement:* The study is compliant with ethical standards. Considering the design of the study no human or animal rights were infringed upon.

*Informed consent:* Considering the design of the study no informed consent was necessary.

**REFERENCES:**

1. Lonergan ZR, Skaar EP. Nutrient Zinc at the Host–Pathogen Interface. Trends in Biochemical Sciences 2019. https://doi.org/10.1016/j.tibs.2019.06.010
2. Maret W. The redox biology of redox-inert zinc ions. Free Radical Biology & Medicine. 2019;134:311-326. DOI: 10.1016/j.freeradbiomed.2019.01.006.
3. Prasad AS. Discovery of human zinc deficiency: its impact on human health and disease. Adv Nutr. 2013 Mar 1;4(2):176-90. doi: 10.3945/an.112.003210.
4. de Faria Coelho-Ravagnani C, Corgosinho FC, Sanches FFZ, Prado CMM, Laviano A, Mota JF. Dietary recommendations during the COVID-19 pandemic. Nutr Rev. 2021 Mar 9;79(4):382-393. doi: 10.1093/nutrit/nuaa067.
5. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients. 2020;12(4). :1181. Doi: 10.3390/nu12041181
6. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed [12 January 2021].
7. Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Front Immunol. 2020; 11:1712. https://doi.org/10.3389/fimmu.2020.01712
8. https://pubmed.ncbi.nlm.nih.gov/?term=%28%28Zinc%29+AND+%28COVID-19%29%29+AND+%28 treatment%29&sort=)
9. https://www.newhope.com/market-data-and-analysis/market-overview-2020-supplement-sales-shift-changing-trends-and-refocused [Accessed 12 Jan 2021]
10. https://www.kktv.com/content/news/Zinc-sales-skyrocket-at-supplement-manufacturing-company-amid-pandemic-569900931.html [Accessed 12 Jan 2021]
11. https://timesofindia.indiatimes.com/business/india-business/multivitamin-tops-drug-sales-for-1st-time-in-oct/articleshow/79768560.cms [Accessed 12 Jan 2021]
12. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. Adv Nutr. 2019 Jul 1;10(4):696-710. Doi: 10.1093/advances/nmz013. PMID: 31305906; PMCID: PMC6628855.
13. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PloS Pathog. 2010;6(11):e1001176
14. Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PloS one, 7(11): e50568
15. Prasad, AS, Brewer, GJ, Schoomaker, EB, et al. Hypocupremia Induced by Zinc Therapy in Adults. JAMA. 1978;240(20):2166-2168. Doi:10.1001/jama.1978.03290200044019
16. Bonaventura P, Benedetti G, Albarède F, Miossec P. Zinc and its role in immunity and inflammation. Autoimmun Rev. 2015 Apr;14(4):277-85. doi: 10.1016/j.autrev.2014.11.008.
17. Kimura, T. and Kambe, T. (2016) The functions of metallothionein and ZIP and ZnT transporters: an overview and perspective. Int. J. Mol. Sci. 17, 336
18. Rink, L. and Haase, H. (2007) Zinc homeostasis and immunity. Trends Immunol. 28, 1–4
19. Hood MI, Skaar EP. Nutritional immunity: transition metals at the pathogen–host interface. Nat Rev Microbiol. 2012; 10: 525-537. doi:10.1038/nrmicro2836

20. Nishime K, Kondo M, Saito K, Miyawaki H, Nakagawa T. Zinc Burden Evokes Copper Deficiency in the Hypoalbuminemic Hemodialysis Patients. Nutrients. 2020 Feb 23;12(2):577. Doi: 10.3390/nu12020577. PMID: 32102170; PMCID: PMC7071503.

21. Milton AH, Vashum KP, McEvoy M, Hussain S, McElduff P, Byles J, Attia J. Prospective Study of Dietary Zinc Intake and Risk of Cardiovascular Disease in Women. Nutrients 2018, 10, 38; doi:10.3390/nu10010038

22. Qu X, Yang H, Yu Z, Jia B, Qiao H, Zheng Y, Dai K. Serum zinc levels and multiple health outcomes: Implications for zinc-based biomaterials. Bioact Mater. 2020 Mar 31;5(2):410-422. Doi: 10.1016/j.bioactmat.2020.03.006

23. CDC. Your Health: People with Certain Medical Conditions. Centers for Disease Control and Prevention (CDC), U.S. Department of Health & Human Services, 2020 (Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases) (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html; Updated 29 December 2020)

24. Worldometer. https://www.worldometers.info [Online Resource]. COVID-19 Coronavirus Pandemic. Available at https://www.worldometers.info/coronavirus/; Life Expectancy of the World Population. Available at https://www.worldometers.info/demographics/life-expectancy/, source: United Nations Population Division. World Population Prospects: The 2019 Revision; [Accessed on July 4, 2021]

25. Our World in Data. Published online at OurWorldInData.org [Online Resource]. Max Roser, Hannah Ritchie, Esteban Ortiz-Ospina and Joe Hasell (2020) – "Coronavirus Pandemic (COVID-19)". Available at 'https://ourworldindata.org/coronavirus'; Healthcare Access and Quality Index. Available at https://ourworldindata.org/grapher/healthcare-access-and-quality-index, source link http://ghdx.healthdata.org/record/global-burden-disease-study-2015-gbd-2015-healthcare-access-and-quality-index-based-amenable; Max Roser, Esteban Ortiz-Ospina and Hannah Ritchie (2013) - "Life Expectancy". Available at 'https://ourworldindata.org/life-expectancy' [Online Resource; last revised October 2019]; Median Age. Available at https://ourworldindata.org/age-structure, sourced from UN Population Division, World Population Prospects, 2017 Revision, source link: https://esa.un.org/unpd/wpp/Download/Standard/Population/

26. Singh S, Maurya RP, Singh RK. "Trained immunity" from Mycobacterium spp. Exposure or BCG vaccination and COVID-19 outcomes. PloS Pathog. 2020 Oct 29;16(10):e1008969. Doi: 10.1371/journal.ppat.1008969. PMID: 33119725.

27. Singh S. BCG Vaccines May Not Reduce Covid-19 Mortality Rates. medRxiv2020.04.11.20062232. https://doi.org/10.1101/2020.04.11.20062232

28. Escobara LE, Molina-Cruzb A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS 2020; 117: 17720-17726; www.pnas.org/cgi/doi/10.1073/pnas.2008410117

29. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. Aging Clin Exp Res 2020; 32:1609–1612 DOI: 10.1007/s40520-020-01619-8

30. Singh S. Covariation of Zinc Deficiency with COVID-19 Infections and Mortality in European Countries: Is Zinc Deficiency a Risk Factor for COVID-19? medRxiv; 2020. DOI: 10.1101/2020.06.12.20105676. & Journal of Scientific Research. 2020; 64(2):153-157. http://dx.doi.org/10.37398/JSR.2020.640222 (ISSN: 0447-9483)

31. Arlehamna CSL, Settea A, Peters B. Lack of evidence for BCG vaccine protection from severe COVID-19. PNAS 2020; 117: 25203–25204; www.pnas.org/cgi/doi/10.1073/pnas.2016733117

32. Palmer, L.D. and Skaar, E.P. (2016) Transition metals and virulence in bacteria. Annu. Rev. Genet. 50, 67–91

33. Aydemir, T.B. et al. (2012) Zinc transporter ZIP14 functions in hepatic zinc, iron and glucose homeostasis during the innate immune response (endotoxemia). PLoS One 7, e48679

34. Pyle CJ, Azad AK, Papp AC, Sadee W, Knoell DL, Schlesinger LS. Elemental Ingredients in the Macrophage Cocktail: Role of ZIP8 in Host Response to Mycobacterium tuberculosis. Int J Mol Sci. 2017 Nov 9;18(11):2375. doi: 10.3390/ijms18112375.

35. Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem. 1998 May 15;273(20):12427-35. doi: 10.1074/jbc.273.20.12427.

36. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007 Sep;13(9):1042-9. doi: 10.1038/nm1638.

37. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003 Jun;26(6):753-60. doi: 10.1248/bpb.26.753

38. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, et al. Metal chelation and inhibition of bacterial growth in tissue abscesses. Science. 2008;319(5865):962-5. doi: 10.1126/science.1152449.

39. Besold AN, Gilston BA, Radin JN, Ramsoomair C, Culbertson EM, Li CX, et. al. Role of Calprotectin in Withholding Zinc and Copper from Candida albicans. Infect Immun. 2018 Jan 22;86(2):e00779-17. doi: 10.1128/IAI.00779-17.

40. Wang J, Lonergan ZR, Gonzalez-Gutierrez G, Nairn BL, Maxwell CN, Zhang Y, et al. Multi-metal Restriction by Calprotectin Impacts De Novo Flavin Biosynthesis in Acinetobacter baumannii. Cell Chem Biol. 2019 May 16;26(5):745-755.e7. doi: 10.1016/j.chembiol.2019.02.011.

41. Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020 Jan 16;12(1):236. doi: 10.3390/nu12010236.

42. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. Cochrane Database Syst Rev 2014, Cd009384.

43. World Health Organization. Zinc supplementation in children with respiratory infections e-Library of Evidence for Nutrition Actions (eLENA). World Health Organization (updated 11 February 2019) (https://www.who.int/elena/titles/zinc_pneumonia_children/en/; Accessed on 12 October 2020)

44. Bao S, Knoell DL. Zinc modulates airway epithelium susceptibility to death receptor- mediated apoptosis. American Journal of Physiology – Lung Cellular and Molecular Physiology. 2006; 290:L433–L441.

45. World Health Organization. Guideline: Nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013. ISBN: 978 92 4 150641 0 (https://apps.who.int/iris/bitstream/handle/10665/94836/9789241506410_eng.pdf;jsessionid=BE

E74AC32E3B6835C757E6787332B883?sequence=1
https://www.who.int/nutrition/publications/guidelines/nutcare_support_patients_with_tb/en/)

46. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD006086. DOI: 10.1002/14651858.CD006086.pub4. [Accessed 14 January 2021]

47. Freiberg MS, Cheng DM, Gnatienko N, et al. Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(5):e204330. Doi:10.1001/jamanetworkopen.2020.4330

48. Brown KH. Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. Am J Clin Nutr 1998;68(suppl):425S–9S.

49. Hess SY, Peerson JM, King JC, Brown KH. Use of serum zinc concentration as an indicator of population zinc status. Food Nutr Bull. 2007 Sep;28(3 Suppl):S403-29. doi: 10.1177/15648265070283S303.

50. Cabrera AJR. Zinc, aging, and immunosenescence: an overview. Pathobiology of Aging & Age-related Diseases 2015, 5: 25592 – http://dx.doi.org/10.3402/pba.v5.25592

51. Khawaja SA, Mohan P, Jabbour R, et alCOVID-19 and its impact on the cardiovascular systemOpen Heart 2021;8:e001472. doi: 10.1136/openhrt-2020-001472

52. Agnew UM, Slesinger TL. Zinc Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554548/ [Updated 2020 May 7].

53. Rochwerg B, Siemieniuk R A, Agoritsas T, Lamontagne F, Askie L, Lytvyn L et al. A living WHO guideline on drugs for covid-19 BMJ 2020; 370 :m3379 doi:10.1136/bmj.m3379 (last updated 31 March 2021; 'Therapeutics and COVID-19: living guideline' available at https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1)

54. Siemieniuk R A, Bartoszko J J, Ge L, Zeraatkar D, Izcovich A, Kum E et al. Drug treatments for covid-19: living systematic review and network meta-analysis BMJ 2020; 370 :m2980 doi:10.1136/bmj.m2980 (last updated 06 April 2021)

55. Briggs MH, Briggs M, Austin J. Effects of steroid pharmaceuticals on plasma zinc. Nature. 1971 Aug 13;232(5311):480-1. doi: 10.1038/232480a0. PMID: 4937210.

56. Yunice AA, Czerwinski AW, Lindeman RD. Influence of synthetic corticosteroids on plasma zinc and copper levels in humans. Am J Med Sci. 1981 Sep-Oct;282(2):68-74. doi: 10.1097/00000441-198109000-00003. PMID: 7325187.

57. Ellul-Micallef R, Galdes A, Fenech FF. Serum zinc levels in corticosteroid-treated asthmatic patients. Postgrad Med J. 1976;52(605):148-150. doi:10.1136/pgmj.52.605.148

58. Karin M, and Herschman HR. Induction of Metallothionein in HeLa Cells by Dexamethasone and Zinc. Eur J Biochem, 1981; 113: 267-272. https://doi.org/10.1111/j.1432-1033.1981.tb05062.x

59. Kobayashi S, Okada T, Kimura M. Effects of dexamethasone on metallothionein induction by Zn, Cu, and Cd in Chang liver cells. Chem Biol Interact. 1985 Nov;55(3):347-56. doi: 10.1016/s0009-2797(85)80141-1

60. Hanada K, Sawamura D, Nakano H, Hashimoto I. Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. J Dermatol Sci. 1995 May;9(3):203-8. doi: 10.1016/0923-1811(94)00378-r.

**Figure Legends:**

**Fig. 1. Zinc sufficiency of the socially similar European populations correlated with COVID-19 mortality.** Study populations: **(A)** Zn sufficiency estimates, **(B)** and **(C)** deaths and cases/million (26th April). [Note: Global maps [18] displayed color scheme variations performed using 'Inkscape']. Deaths **(D)** and cases **(E)** per million population positively correlated with their Zn sufficiency levels. **(F)** For the group of countries with different Zn sufficiency (suff.) the interim case fatality ratio [i-CFR or Avg. CFR = (reported deaths/ reported cases) *100] remained different throughout the period after peaking in May 2020. **(G)** Fold change in the relative CFR for high suff. with respect to low suff. countries have been registering a steady increase while the gap for cases has kept shrinking.

**Table 1. COVID-19 incidences and mortality in socially similar European populations**

**Table 2. Correlation Analysis of COVID-19 mortality and incidence with Zinc sufficiency of populations.** Correlation analysis for the most synchronized period of SARS-CoV-2 infections in twenty-three socially similar European countries (highlighted yellow period – covers the rise and flattening of COVID-19 case and mortality rate (see Supp. Fig. 2). P-value <0.05 is referred to as statistically significant.

**Supplementary Figure 1. Globally, Zinc sufficiency levels are positively associated with COVID-19 impact on populations. (A)** Zinc levels vary across countries. European (EU) and North American (NA) countries (red box) with higher development index, more diversified diet, with food fortification in place had higher Zn sufficiency. **(B)** The mortality per million population in socially similar EU and NA countries at a similar stage of 1st wave strongly covary with Zn sufficiency (higher sufficiency- higher deaths). *For analysis of European nations see the main manuscript.* **(C)** Cases per million across countries. Images adapted from refs. 14, 25

**Supplementary Figure 2.** The wave of COVID-19 deaths (8 out of 10 were elderly) **(A)** and incidences (majority younger – without dysregulated Zn homeostasis) **(B)** as it traversed the countries analyzed in the current study

**Supplementary Table 1. COVID-19 incidences and mortality in socially similar European populations up to 26 August 2020**

**Fig. 1. Zinc sufficiency of the socially similar European populations correlated with COVID-19 mortality.** Study populations: **(A)** Zn sufficiency estimates, **(B)** and **(C)** deaths and cases/million (26th April). [Note: Global maps (25) displayed color scheme variations performed using 'Inkscape']. Deaths **(D)** and cases **(E)** per million population positively correlated with their Zn sufficiency levels. **(F)** For the group of countries with different Zn sufficiency the interim case fatality ratio [i-CFR or Avg. CFR' = (reported deaths/ reported cases)*100] remained different throughout the period after peaking in May 2020. **(G)** Fold change in the relative CFR for high sufficiency (Suff.) with respect to low suff. countries has been registering a steady increase while the gap for cases has kept shrinking.

## Table 1. COVID-19 incidences and mortality in socially similar European populations

| [1]COUNTRIES | [2]CpM 12 Mar | [2]DpM 12 Mar | CpM 26 Mar | DpM 26 Mar | CpM 12 Apr | DpM 12 Apr | CpM 26 Apr | DpM 26 Apr | CpM 12 May | DpM 12 May | CpM 26 May | DpM 26 May | CpM 12 Jun | DpM 12 Jun | CpM 26 Jun | DpM 26 Jun | Population | [3]% Zn Def. (2005) | [3]% Zn Suff. (2005) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iceland | 342.51 | 0.00 | 2347.79 | 5.85 | 4979.54 | 23.42 | 5245.93 | 29.27 | 5272.28 | 29.27 | 5281.06 | 29.27 | 5289.84 | 29.27 | 5327.90 | 29.27 | 341598 | 3.10 | 96.90 |
| France | 44.04 | 0.93 | 446.50 | 25.97 | 1461.06 | 220.22 | 1907.82 | 349.69 | 2147.53 | 412.99 | 2229.12 | 436.54 | 2393.48 | 449.47 | 2495.31 | 455.66 | 65296963 | 3.90 | 96.10 |
| Ireland | 14.15 | 0.20 | 367.73 | 3.84 | 1950.46 | 67.52 | 3892.64 | 218.94 | 4697.25 | 300.01 | 4999.08 | 325.68 | 5103.19 | 343.88 | 5136.34 | 348.93 | 4946514 | 4.00 | 96.00 |
| Finland | 19.67 | 0.00 | 172.86 | 0.90 | 536.62 | 10.10 | 825.68 | 34.28 | 1083.16 | 49.62 | 1195.93 | 56.30 | 1276.23 | 58.64 | 1297.52 | 59.18 | 5542120 | 4.60 | 95.40 |
| UK | 7.89 | 0.13 | 155.54 | 12.92 | 1123.82 | 180.71 | 2038.02 | 352.76 | 3019.69 | 472.95 | 3536.57 | 532.41 | 3906.24 | 577.36 | 4125.05 | 592.38 | 67943420 | 4.60 | 95.40 |
| Switzerland | 100.18 | 0.81 | 1363.11 | 22.16 | 2933.15 | 127.64 | 3353.93 | 185.81 | 3506.16 | 215.47 | 3550.13 | 221.01 | 3584.98 | 223.66 | 3633.80 | 226.43 | 8664751 | 4.90 | 95.10 |
| Netherlands | 35.82 | 0.29 | 433.52 | 25.32 | 1492.73 | 159.68 | 2207.86 | 261.07 | 2507.67 | 321.45 | 2659.00 | 341.64 | 2827.19 | 353.13 | 2917.21 | 356.05 | 17141028 | 5.00 | 95.00 |
| Spain | 665.43 | 1.84 | 3118.24 | 93.35 | 4667.48 | 368.05 | 5243.71 | 495.96 | 5493.08 | 574.36 | 5622.58 | 595.47 | 5738.28 | 604.71 | 5819.68 | 606.06 | 46757733 | 5.40 | 94.60 |
| Italy | 250.17 | 16.87 | 1333.08 | 136.33 | 2586.60 | 330.19 | 3269.98 | 441.89 | 3659.54 | 512.71 | 3814.12 | 546.69 | 3909.39 | 567.70 | 3970.11 | 576.73 | 60447245 | 5.80 | 94.20 |
| Sweden | 76.27 | 0.10 | 296.36 | 13.26 | 1079.30 | 134.03 | 1865.89 | 253.13 | 2775.15 | 369.85 | 3523.17 | 438.21 | 4982.21 | 500.53 | 6450.65 | 536.53 | 10109375 | 6.10 | 93.90 |
| Norway[5] | 147.38 | 0.18 | 621.22 | 2.58 | 1202.10 | 23.58 | 1386.69 | 37.03 | 1502.76 | 42.00 | 1544.40 | 43.29 | 1588.06 | 44.58 | 1627.11 | 45.87 | 5428015 | 6.20 | 93.80 |
| Denmark[5] | 116.30 | 0.00 | 323.87 | 7.07 | 1065.31 | 47.11 | 1479.60 | 72.82 | 1827.45 | 90.93 | 1971.87 | 97.14 | 2072.12 | 102.49 | 2187.04 | 104.22 | 5795502 | 6.20 | 93.80 |
| Portugal | 7.65 | 0.00 | 347.73 | 5.89 | 1627.29 | 49.45 | 2324.22 | 88.60 | 2738.77 | 114.11 | 3042.34 | 131.67 | 3549.91 | 147.67 | 4009.69 | 152.57 | 10191814 | 6.30 | 93.70 |
| Belgium | 34.40 | 0.34 | 537.60 | 41.30 | 2556.27 | 370.16 | 3977.84 | 627.10 | 4637.01 | 753.16 | 4953.97 | 797.05 | 5157.80 | 821.97 | 5268.77 | 829.30 | 11597764 | 6.80 | 93.20 |
| Lithuania | 1.102 | 0 | 100.651 | 1.469 | 386.807 | 8.449 | 523.824 | 15.061 | 545.496 | 18.367 | 600.597 | 23.142 | 643.576 | 27.183 | 663.412 | 28.652 | 2725537 | 7.5 | 92.50 |
| Hungary | 1.66 | 0.00 | 27.03 | 1.04 | 146.02 | 10.25 | 258.90 | 28.17 | 343.09 | 44.01 | 390.52 | 51.68 | 419.73 | 57.48 | 427.39 | 59.86 | 9656316 | 8.40 | 91.60 |
| Germany | 32.75 | 0.07 | 524.15 | 3.19 | 1525.21 | 36.05 | 1882.08 | 71.29 | 2065.81 | 92.31 | 2162.64 | 101.38 | 2233.77 | 105.73 | 2319.04 | 107.67 | 83827321 | 9.00 | 91.00 |
| Poland | 0.819 | 0 | 27.77 | 0.37 | 167.941 | 5.496 | 297.86 | 13.845 | 431.373 | 21.429 | 571.544 | 26.607 | 745.139 | 32.103 | 875.085 | 37.308 | 37850425 | 10.3 | 89.70 |
| Estonia | 20.35 | 0.00 | 405.52 | 0.75 | 986.67 | 18.84 | 1238.43 | 36.93 | 1316.07 | 45.98 | 1382.40 | 47.49 | 1484.91 | 47.49 | 1496.97 | 47.49 | 1326680 | 10.50 | 89.50 |
| Czechia | 10.92 | 0.00 | 189.32 | 0.84 | 561.32 | 12.88 | 693.23 | 20.54 | 769.50 | 26.42 | 846.98 | 29.59 | 929.87 | 30.71 | 1032.56 | 32.39 | 10712210 | 11.00 | 89.00 |
| Ukraine | 0.00 | 0.00 | 2.584 | 0.091 | 57.416 | 1.669 | 185.783 | 4.596 | 357.801 | 9.329 | 485.78 | 14.245 | 664.704 | 19.527 | 914.808 | 24.398 | 43757273 | 11.4 | 88.60 |
| Bulgaria | 1.007 | 0.144 | 34.828 | 0.432 | 95.129 | 4.03 | 179.465 | 7.915 | 286.395 | 13.384 | 350.15 | 18.709 | 444.128 | 24.178 | 634.387 | 30.367 | 6953085 | 15.3 | 84.70 |
| Slovakia | 3.85 | 0.00 | 41.39 | 0.00 | 135.90 | 0.37 | 252.56 | 3.30 | 268.31 | 4.94 | 277.10 | 5.13 | 282.41 | 5.13 | 300.91 | 5.13 | 5460073 | 16.30 | 83.70 |
| **Average (High Zn suff.≥93.8 % countries(12)** | 151.65 | 1.78 | 914.99 | 29.13 | 2089.85 | 141.02 | 2726.48 | 227.72 | 3124.31 | 282.64 | 3327.25 | 305.31 | 3555.93 | 321.29 | 3748.98 | 328.11 | | 4.98 | 95.02 |
| **STDEV** | 191.10 | 4.78 | 952.49 | 41.97 | 1443.75 | 118.60 | 1472.46 | 162.11 | 1448.39 | 195.01 | 1460.40 | 210.62 | 1525.52 | 222.57 | 1690.16 | 227.95 | Pop. 298414264 | 1.00 | 1.00 |
| **Average (Low Zn suff. countries <93.8% (11)** | 10.41 | 0.05 | 203.51 | 5.03 | 749.63 | 47.06 | 1074.02 | 83.40 | 1250.87 | 103.95 | 1369.46 | 113.34 | 1505.09 | 119.92 | 1631.18 | 123.19 | | 10.25 | 89.75 |
| **STDEV** | 12.95 | 0.11 | 210.70 | 12.15 | 827.40 | 108.24 | 1210.52 | 182.42 | 1388.03 | 218.12 | 1474.75 | 230.05 | 1555.97 | 236.58 | 1611.60 | 237.97 | Pop. 224058498 | 3.23 | 3.23 |

Note:

1. Countries socially similar with supposedly comparable  confounders ref 1,2.)
2. CpM: Cases per million; DpM: Deaths per million; Mar: March; Apr: April; Jun: June; Jul: July; Aug: August. 2020
3. Zn deficiency (def.; Sufficiency (suff. = 100-Def.) estimates for populations based upon overall intake (e.g, food, fortified articles) and stunting prevalence from Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PloS one, 7(11) : e50568. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510072/
4. STDEV: Standard deviation

5. If these countries also included in LOW Suff. group the mortality and incidence rate gap with HIGH Suff. countries will increase further. However for the sake of keeping groups almost equal sized, we preferred to err to show lesser difference between the two group of countries, as we still do not have the cause and effect evidence for the association observed.

| **CORRELATION ANALYSIS** | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **Data-Date** | **12 Mar** | *26 Mar* | *12 Apr* | *26 Apr* | *12 May* | *26 May* | *12 Jun* | *26 Jun* |
| **Average Deaths/Million Pop. ± STDEV** | 0.95 ± 3.50 | 17.61 ± 33.16 | 96.08 ± 121.08 | 158.70 ± 183.58 | 197.18 ± 221.29 | 213.49 ± 236.32 | 224.98 ± 246.55 | 230.11 ± 250.35 |
| **DEATHS/Million(Log) *vs* Zn SUFF. - Correlation *r* (23):** | **0.3731** | **0.7893** | **0.7642** | **0.7455** | **0.7213** | **0.7099** | **0.6989** | **0.6849** |
| ***p*-value** | 0.0795 | 7.6E-06 | 2.19E-05 | 4.5E-05 | 0.0001 | 0.0001 | 0.0002 | 0.0003 |
| | | | | | | | | |
| **Average Cases/million Pop. ± STDEV** | 84.10 ± 153.42 | 574.71 ± 778.36 | 1448.88 ± 1349.80 | 1936.17 ±1569.23 | 2228.32 ± 1685.30 | 2390.92 ± 1747.82 | 2575.09 ± 1833.38 | 2736.12 ± 1943.94 |
| **CASES/Million (Log) *vs* Zn SUFF. - Correlation *r* (23):** | **0.5658** | **0.6513** | **0.7681** | **0.7906** | **0.8067** | **0.8084** | **0.7966** | **0.7629** |
| ***p*-value** | 0.0049 | 0.0008 | 1.88E-05 | 7.1E-06 | 3.33E-06 | 3.05E-06 | 5.42E-06 | 2.3E-05 |

**Table 2. Correlation Analysis of COVID-19 mortality and incidence with Zinc sufficiency of populations.**
Correlation analysis for the most synchronized period of infections and response in twenty-three socially similar European countries (highlighted yellow period – covers the rise and flattening of infections/mortality rate (see Supp. Fig. 2). P-value <0.05 is referred to as statistically significant.

**Supplementary Figure 1. Globally, Zinc sufficiency levels positively associated with COVID-19 impact on populations. (A)** Zinc levels vary across countries. European (EU) and North American (NA) countries (red box) with higher development index more diverse diet and food fortification had higher Zn sufficiency. **(B) The mortality per million population in socially similar EU and NA countries and similar stage of pandemic strongly covary (higher sufficiency- higher deaths).** *For analysis of European nations see main manuscript.* (C) Cases per million across countries. Images adapted from refs. 14,25

**Supplementary Figure 2.** The wave of COVID-19 deaths (8 out of 10 were elderly) **(A)** and incidences (majority younger – without dysregulated Zn homeostasis) **(B)** as it traversed the countries analyzed in the current study